+49 40 6094087 0
At Kappa Bioscience we are proud to offer you high purity vitamin K2 as menaquinone 7 (MK 7)
Kappa's 2019 Formulation LookBook is a compendium of 150 ready-to-launch white-label product concepts that are backed by consumer market reseach, stability trials and established supply chains.
As the innovative leader and first mover of vitamin K2 MK 7, we have extensive knowledge about vitamins and are currently the only vendor with vitamin K2 as pure MK 7 in various formulations.
Founded in December 2006, Kappa Bioscience is a Norwegian based entity that takes pride in following a traditional vitamin production process with propriety and innovative new steps. One of our core assets is the patent covering the production of pure vitamin K2 as menaquinone 7.
Our main focus is to develop vitamin K2 for the food supplement and fortified foods market.
Vitamin K2 is currently gaining momentum across the world and as it does, we intend to continue to serve the market with pure and stable forms of MK 7 products.
All of our products have been developed in close collaboration with highly qualified Norwegian and international scientists, who have been able to successfully accomplish the difficult process of producing menaquinone 7.
We are proud to launch the first man made menaquinone 7 in its natural form as K2VITAL.
Sales and Marketing
Kappa Ingredients GmbH
Friesenweg 4 | Building 13 | 22763 Hamburg
Hear from @AtlantiaT, @Kappabio and @novatuits on the importance tradeshows to enable human connection and knowledge sharing for commercial success and how they are adapting to new challenges...#BusinessContinuity #exhibitor #cpgbrands— Vitafoods Insights (@vfoodsinsights) March 25, 2020
"Big THANKS to the team at Informa - especially @ChrisLee1978 - for taking an uneasy decision. Knowing they've been working night and day to make it happen in September deserves great respect. May all of u stay healthy and participate in the best VFE show ever - in summer 2020!" https://t.co/Rt7HISs7AS— Kappa Bioscience AS (@Kappabio) March 11, 2020